Gilead Sciences Inc.
Large Cap · Healthcare · Drug Manufacturers - General
$138.36+$0.22 (+0.16%)
Gilead Sciences Inc.
Large Cap · Healthcare · Drug Manufacturers - General
$138.36+$0.22 (+0.16%)
Stock analysis
Get the AI take on GILD
Track it to unlock the price chart, verdict and what could change it.
- ✓Live price chart
- ✓A clear accumulate, trim or avoid call
Free to track. No card required.
Stock Fundamentals & Key Indicators
52-week range
Low$107.75
High$157.29
Today $138.36
RSI (14)
62.1Neutral
03070100
Overall score
73/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
Analyst Rating and Sentiment
Analyst price targets
Lowest
$123
Current price
$138.36
Median target
$160
Highest
$180
LowHigh
Operating Record
Revenue
What's working
- Forward P/E: Investors aren't pricing in much earnings growth, so there's room to be pleasantly surprised.
- Price / FCF: Real cash coming through the door backs up what you're paying.
What to watch
- Debt exceeds cash by $21.4B, increasing balance-sheet pressure, a warning sign.
What the market charges
Forward P/E
Favorable · 28% below avg
15.14x
Price / sales
Reasonable · Priced reasonably against its revenue
5.63x
Price / FCF
Strong · Priced well within what its cash flow supports
13.26x
EV / EBITDA
Reasonable · Operating earnings make this price a stretch but plausible
13.21x
How efficiently it compounds
ROIC
Strong · Comfortably clears the bar for efficient capital use
34.4%
ROE
Favorable · 43.2% - strong capital efficiency
-20.7%
Debt / equity
Middle ground · Mixed
2.23x
Current ratio
Reasonable · Just enough on hand to cover near-term bills
1.27x
Peer Comparison
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $171.56B | 18.1 | +5.5% | 73 |
 | $11.53B | 22.0 | +19.7% | 78 |
 | $4.60B | 13.9 | +13.5% | 77 |
 | $33.87B | 35.4 | +15.5% | 77 |
 | $1.11T | 40.1 | +49.6% | 76 |
